4
Changes in Ownership
Tarsus Pharmaceuticals, Inc. Filed Acc 0001519692-23-000006
Chief Financial Officer sold 5,313 shares at an average $13.44 ($71,404)
- Chief Financial Officer acquired 4,462 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Greenstein Leonard M. · Chief Financial Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-03-15 | Exercise or conversion : show line 1 in the form | +4,462 | 38,751 | D | ||
| 2023-03-16 | Sale : show line 2 in the form | −313 | $13.43 | $4,204 | 38,438 | D |
| 2023-03-16 | Sale : show line 3 in the form | −5,000 | $13.44 | $67,200 | 33,438 | D |
| Open-market sales · 5,313 sh · avg $13.44 · $71,404 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-03-15 | Exercise or conversion : show line 4 in the form Restricted Stock Units | −4,462 | 13,388 | D |
Loading xslF345X03/wf-form4_167909066577368.xml…